These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26195507)

  • 21. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.
    Alsaad N; van Altena R; Pranger AD; van Soolingen D; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
    Eur Respir J; 2013 Aug; 42(2):504-12. PubMed ID: 23100498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
    Zvada SP; Denti P; Sirgel FA; Chigutsa E; Hatherill M; Charalambous S; Mungofa S; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2014; 58(1):503-10. PubMed ID: 24189253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.
    Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ofloxacin induced arthropathy in patients with multi-drug resistance tuberculosis.
    Tumbanatham A; Vinodkumar S
    J Assoc Physicians India; 2000 Jun; 48(6):647-8. PubMed ID: 11273550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
    Chierakul N; Klomsawat D; Chulavatnatol S; Chindavijak B
    Int J Tuberc Lung Dis; 2001 Mar; 5(3):278-82. PubMed ID: 11326828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
    Ghimire S; Maharjan B; Jongedijk EM; Kosterink JGW; Ghimire GR; Touw DJ; van der Werf TS; Shrestha B; Alffenaar JC
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
    van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
    Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
    Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of multidrug-resistant tuberculosis in Indonesia.
    Hadiarto M; Tjandra YA; Hudoyo A
    Chemotherapy; 1996; 42 Suppl 3():24-9. PubMed ID: 8980865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
    Van der Walt M; Lancaster J; Odendaal R; Davis JG; Shean K; Farley J
    PLoS One; 2013; 8(4):e58817. PubMed ID: 23573193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003.
    Feja K; McNelley E; Tran CS; Burzynski J; Saiman L
    Pediatr Infect Dis J; 2008 Oct; 27(10):907-12. PubMed ID: 18756183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
    Kempker RR; Barth AB; Vashakidze S; Nikolaishvili K; Sabulua I; Tukvadze N; Bablishvili N; Gogishvili S; Singh RS; Guarner J; Derendorf H; Peloquin CA; Blumberg HM
    Antimicrob Agents Chemother; 2015; 59(6):3149-55. PubMed ID: 25779583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
    Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
    Chigutsa E; Meredith S; Wiesner L; Padayatchi N; Harding J; Moodley P; Mac Kenzie WR; Weiner M; McIlleron H; Kirkpatrick CM
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3857-63. PubMed ID: 22564839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.
    Modongo C; Pasipanodya JG; Magazi BT; Srivastava S; Zetola NM; Williams SM; Sirugo G; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5928-32. PubMed ID: 27458224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
    Peloquin CA; Phillips PPJ; Mitnick CD; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Kaur P; Horsburgh CR
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015.
    Ködmön C; van den Boom M; Zucs P; van der Werf MJ
    Euro Surveill; 2017 Nov; 22(47):. PubMed ID: 29183553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.